MILLENNIUM PHARMACEUTICALS, INC.

Multiple myeloma remains incurable, with diminishing relief from subsequent therapies. Amin Sobh, PhD, identified adenylate kinase 2 (AK2) as a promising target for patients with t(4;14) translocation. NSD2 overexpression in these patients leads to increased AK2 dependency, which can be targeted to inhibit myeloma cell growth. Sobh's research highlights the complex interplay between epigenetic dysregulation and cellular metabolism in cancer.

Singapore's Health Products (Therapeutic Products) Regulations updated on 1 August 2024 clarify patent declaration for marketing approval, specifying patents must include claims for active ingredients, formulations, or specific therapeutic uses, excluding those for manufacturing processes, packaging, metabolites, or intermediates.

Study on MM treatment decision-making highlights QoL, duration of response, and side effects as top attributes for patients, care partners, and physicians. Differences in preferences and trade-offs underscore the importance of shared decision-making (SDM) to align treatment plans with patient values and improve outcomes.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

80% of advanced-phase CML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib in a Phase II trial, according to MD Anderson researchers. The trial included patients with accelerated or myeloid blast phases of CML and Philadelphia chromosome-positive AML.

80% of advanced-phase CML or Philadelphia chromosome-positive AML patients achieved bone marrow remission with decitabine, venetoclax, and ponatinib combination therapy in a Phase II trial, published in The Lancet Haematology.